| scholarly article | Q13442814 |
| P356 | DOI | 10.1002/PBC.25608 |
| P698 | PubMed publication ID | 26173735 |
| P50 | author | Phu-Quoc Lê | Q80465514 |
| Laurence Rozen | Q82340353 | ||
| P2093 | author name string | Alina Ferster | |
| Catherine Heijmans | |||
| Christine Devalck | |||
| Laurence Dedeken | |||
| Sophie Huybrechts | |||
| Fleur Samantha Benghiat | |||
| Sophie Dupont | |||
| Béatrice Gulbis | |||
| Marie-Françoise Dresse | |||
| André Efira | |||
| Anna Vanderfaeillie | |||
| P2860 | cites work | Acute clinical events in 299 homozygous sickle cell patients living in France. French Study Group on Sickle Cell Disease | Q46846124 |
| Prevention of a first stroke by transfusions in children with sickle cell anemia and abnormal results on transcranial Doppler ultrasonography | Q47906551 | ||
| Matched-related donor transplantation for sickle cell disease: report from the Center for International Blood and Transplant Research. | Q50697314 | ||
| The effect of hydroxcarbamide therapy on survival of children with sickle cell disease. | Q51065755 | ||
| Trends in pediatric sickle cell disease-related mortality in the United States, 1983-2002. | Q51946241 | ||
| Bone marrow transplantation for sickle cell disease. | Q54087053 | ||
| Mortality in sickle cell disease. Life expectancy and risk factors for early death. | Q55065788 | ||
| Effectiveness of the 7-valent pneumococcal conjugate vaccine in children with sickle cell disease in the first decade of life | Q57219845 | ||
| Clinical outcomes in children with sickle cell disease living in England: a neonatal cohort in East London | Q58320124 | ||
| Long-term results of related myeloablative stem-cell transplantation to cure sickle cell disease | Q58416036 | ||
| Management of sickle cell disease: summary of the 2014 evidence-based report by expert panel members | Q30459060 | ||
| Pulmonary complications of sickle cell disease | Q30515769 | ||
| Hydroxyurea for sickle cell disease: a systematic review for efficacy and toxicity in children | Q33382232 | ||
| Risk factors for death in 632 patients with sickle cell disease in the United States and United Kingdom | Q33837174 | ||
| Improved survival of children and adolescents with sickle cell disease | Q33839801 | ||
| How I use hydroxyurea to treat young patients with sickle cell anemia | Q33985120 | ||
| Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia: risks and benefits up to 9 years of treatment | Q34187983 | ||
| Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia | Q34308407 | ||
| Hydroxycarbamide in very young children with sickle-cell anaemia: a multicentre, randomised, controlled trial (BABY HUG). | Q35097294 | ||
| Survival of children with sickle cell disease | Q35690101 | ||
| Impact of hydroxyurea on clinical events in the BABY HUG trial | Q36425423 | ||
| Outcome of sickle cell anemia: a 4-decade observational study of 1056 patients | Q38471171 | ||
| Sickle cell disease related mortality in the United States (1999-2009). | Q42264563 | ||
| The effect of prolonged administration of hydroxyurea on morbidity and mortality in adult patients with sickle cell syndromes: results of a 17-year, single-center trial (LaSHS). | Q43244775 | ||
| An estimation of the incidence and demographic picture of the major hemoglobinopathies in Belgium (from a confidential inquiry). | Q43916889 | ||
| Impact of early transcranial Doppler screening and intensive therapy on cerebral vasculopathy outcome in a newborn sickle cell anemia cohort | Q44448652 | ||
| Hydroxyurea for sickle cell disease in children and for prevention of cerebrovascular events: the Belgian experience. | Q45190220 | ||
| P433 | issue | 11 | |
| P921 | main subject | Belgium | Q31 |
| sickle-cell disease | Q185034 | ||
| hydroxycarbamide | Q212272 | ||
| P304 | page(s) | 1956-1961 | |
| P577 | publication date | 2015-07-14 | |
| P1433 | published in | Pediatric Blood & Cancer | Q15754342 |
| P1476 | title | Survival among children and adults with sickle cell disease in Belgium: Benefit from hydroxyurea treatment | |
| P478 | volume | 62 |
| Q28086979 | 2015 Clinical trials update in sickle cell anemia |
| Q39269713 | A reappraisal of the mechanisms underlying the cardiac complications of sickle cell anemia |
| Q28828635 | Cellular normoxic biophysical markers of hydroxyurea treatment in sickle cell disease |
| Q38898163 | Cellular therapy for sickle cell disease |
| Q38619234 | Clinical risks and healthcare utilization of haematopoietic cell transplantation for sickle cell disease in the U.S. using merged databases |
| Q89776833 | Cyclophosphamide improves engraftment in patients with SCD and severe organ damage who undergo haploidentical PBSCT |
| Q40460121 | Daily pain in adults with sickle cell disease-a different perspective. |
| Q90365516 | Decreased median survival of adults with sickle cell disease after adjusting for left truncation bias: a pooled analysis |
| Q33427950 | Effects of hydroxyurea treatment for patients with hemoglobin SC disease |
| Q50148088 | Evaluation of newborn sickle cell screening programme in England: 2010-2016. |
| Q38627797 | Evolution of sickle cell disease from a life-threatening disease of children to a chronic disease of adults: The last 40 years |
| Q38851953 | Haematopoietic stem cell transplantation for sickle cell disease - current practice and new approaches |
| Q54735877 | Hydroxycarbamide adherence and cumulative dose associated with hospital readmission in sickle cell disease: a 6-year population-based cohort study. |
| Q39268375 | Hydroxyurea effectiveness in children and adolescents with sickle cell anemia: A large retrospective, population-based cohort |
| Q61908540 | Hydroxyurea for Children with Sickle Cell Anemia in Sub-Saharan Africa |
| Q46853675 | Hydroxyurea prescription, availability and use for children with sickle cell disease in Italy: Results of a National Multicenter survey. |
| Q38586282 | Hydroxyurea therapy for sickle cell anemia |
| Q39312525 | Implementation of multidisciplinary care reduces maternal mortality in women with sickle cell disease living in low-resource setting |
| Q40721306 | Improvement of medical care in a cohort of newborns with sickle-cell disease in North Paris: impact of national guidelines |
| Q26779359 | Indications and Results of HLA-Identical Sibling Hematopoietic Cell Transplantation for Sickle Cell Disease |
| Q48224577 | Lifespan care in SCD: Whom to transition, the patients or the health care system? |
| Q36913577 | Minireview: Clinical severity in sickle cell disease: the challenges of definition and prognostication |
| Q37107206 | Minireview: Prognostic factors and the response to hydroxurea treatment in sickle cell disease |
| Q52666110 | Mortality in children, adolescents and adults with sickle cell anemia in Rio de Janeiro, Brazil. |
| Q38800491 | National registry of hemoglobinopathies in Spain (REPHem). |
| Q38689667 | Neonatal screening improves sickle cell disease clinical outcome in Belgium |
| Q38674500 | Patient Perspectives on Gene Transfer Therapy for Sickle Cell Disease. |
| Q56977890 | Point-of-Care Screening for Sickle-Cell Disease in Low-Resource Settings: a Multi-Center Evaluation of HemoTypeSC, a Novel Rapid Test |
| Q89777671 | Primum non nocere: the case against transplant for children with sickle cell anemia without progressive end-organ disease |
| Q48021426 | Realizing effectiveness across continents with hydroxyurea: Enrollment and baseline characteristics of the multicenter REACH study in Sub-Saharan Africa |
| Q90598059 | Sickle Cell Disease: Advances in Treatment |
| Q37585014 | Sickle cell anemia in sub-Saharan Africa: advancing the clinical paradigm through partnerships and research. |
| Q52795486 | Sickle cell disease. |
| Q48174073 | Sickle cell disease: a malady beyond a hemoglobin defect in cerebrovascular disease |
| Q37258852 | Study protocol for a randomized controlled trial to assess the feasibility of an open label intervention to improve hydroxyurea adherence in youth with sickle cell disease |
| Q91716403 | Targeted Hydroxyurea Education after an Emergency Department Visit Increases Hydroxyurea Use in Children with Sickle Cell Anemia |
| Q44223235 | Therapeutic advances in sickle cell disease in the last decade |
| Q30376725 | Time to Invest in Sickle Cell Anemia as a Global Health Priority. |
| Q37442387 | Translating sickle cell guidelines into practice for primary care providers with Project ECHO. |
| Q46235550 | Validity of simple clinical and biological parameters as screening tool for sickle cell anemia for referral to tertiary center in highly resource constraints. |
Search more.